衞寧健康(300253.SZ):預計2023年淨利潤同比上升223.69%-319.6%
格隆匯1月29日丨衞寧健康(300253.SZ)公佈,預計2023年淨利潤35,100萬元-45,500萬元,比上年同期上升223.69%-319.6%,扣非淨利潤30,800萬元-41,200萬元,比上年同期上升158.37%-245.62%。
2023年,面對複雜嚴峻的外部環境,公司繼續推動以WiNEX系列產品為“1”與互聯網醫院、醫藥險聯動等“X”個數字健康應用場景協調發展,為客户打造全方位的整體解決方案和產品與技術服務體系。報吿期內,公司醫療衞生信息化業務穩健發展,加大成本費用管控力度,同時加大應收賬款的管理和催收;互聯網醫療健康業務持續優化。預計全年公司總的營業收入同比小幅增長。其中,醫療衞生信息化業務收入同比增長約10%以上,互聯網醫療健康業務收入同比下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.